19 June 2013
Keywords: positive, ph, ii, data, esperion, etc-216, promising
Article | 10 November 2003
Promising new data have been published for USA-based EsperionTherapeutics' anti-atherosclerosis drug, ETC-216, in the November 5
issue of the Journal of ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
10 November 2003
© 2013 thepharmaletter.com